Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial

The Lancet

Volumn 387, Issue 10036, 2016, Pages 2402-2411

  Ribrag, Vincent ^a   Koscielny, Serge ^a,b   Bosq, Jacques ^a   Leguay, Thibaut ^c   Casasnovas, Olivier ^d   Fornecker, Luc Mathieu ^e   Recher, Christian ^f   Ghesquieres, Hervé ^g   Morschhauser, Franck ^h   Girault, Stéphane ⁱ   Gouill, Steven Le ^j   Ojeda Uribe, Mario ^k   Mariette, Clara ^l   Cornillon, Jerome ^m   Cartron, Guillaume ⁿ   Verge, Veronique ^a   Chassagne Clément, Catherine ^o   Dombret, Hervé ^p   Coiffier, Bertrand ^q   Lamy, Thierry ^r,s   Tilly, Hervé ^t   Salles, Gilles ^g   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ DE STRASBOURG   (France)

^f Institut Universitaire du Cancer de Toulouse Oncopole   (France)

^g UNIVERSITÉ LYON 1   (France)

^h Univ Lille   (France)

ⁱ LIMOGES UNIVERSITY HOSPITAL   (France)

^j NANTES UNIVERSITY HOSPITAL   (France)

^k Hôpitaux Universitaires de Strasbourg   (France)

^l GRENOBLE UNIVERSITY HOSPITAL   (France)

^m Institut de Cancérologie Lucien Neuwirth   (France)

ⁿ MONTPELLIER UNIVERSITY HOSPITAL   (France)

^o CENTRE LÉON BÉRARD   (France)

^p Section of Radiology   (France)

^q CENTRE HOSPITALIER LYON SUD   (France)

^r Department of Clinical Hematology ^*  (France)

^s RENNES UNIVERSITY HOSPITAL   (France)

^t UNIVERSITÉ DE ROUEN   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; HEMOGLOBIN; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; HYDROCORTISONE; METHYLPREDNISOLONE; TUMOR MARKER;

ADULT; ADVERSE DRUG REACTION; AGE; ALBUMIN BLOOD LEVEL; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BURKITT LYMPHOMA; CENTRAL NERVOUS SYSTEM METASTASIS; CONTROLLED STUDY; DISEASE DURATION; DOSE DENSIFICATION; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; FRANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEROID THERAPY; TREATMENT DURATION; AGED; BONE MARROW NEOPLASMS; CANCER STAGING; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMISTRY; CLINICAL TRIAL; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ODDS RATIO; PATHOLOGY; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BONE MARROW NEOPLASMS; BURKITT LYMPHOMA; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRANCE; HUMANS; HYDROCORTISONE; INJECTIONS, INTRAVENOUS; MALE; METHOTREXATE; METHYLPREDNISOLONE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PATIENT SELECTION; PREDNISONE; PROPORTIONAL HAZARDS MODELS; RITUXIMAB; TREATMENT OUTCOME; VINCRISTINE;

EID: 84980000230     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)01317-3     Document Type: Article

References (31)

1. 1 Bishop, PC, Koneti Rao, V, Wilson, WH, Burkitt's lymphoma: molecular pathogenesis and treatment. Cancer Invest 18 (2000), 574–583.
2. 2 Diviné, M, Lepage, E, Brière, J, et al. Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. J Clin Oncol 14 (1996), 240–248.
3. 3 Longo, DL, Duffey, PL, Jaffe, ES, et al. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to proMACE-based combination chemotherapy. J Clin Oncol 12 (1994), 2153–2159.
4. 4 Jost, LM, Jacky, E, Dommann-Scherrer, C, et al. Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients. Ann Oncol 6 (1995), 445–451.
5. 5 Patte, C, Philip, T, Rodary, C, et al. Improved survival rate in children with stage III and IV B cell non-Hodgkin's lymphoma and leukemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol 4 (1986), 1219–1226.
6. 6 Patte, C, Philip, T, Rodary, C, et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 9 (1991), 123–132.
7. 7 Patte, C, Auperin, A, Michon, J, et al. The Sociéte Française d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97 (2001), 3370–3379.
8. 8 Cairo, MS, Gerrard, M, Sposto, R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 109 (2007), 2736–2743.
9. 9 Patte, C, Auperin, A, Gerrard, M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 109 (2007), 2773–2780.
10. 10 Diviné, M, Casassus, P, Koscielny, S, et al. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol 16 (2005), 1928–1935.
11. 11 Thomas, DA, Cortes, J, O'Brien, S, et al. Hyper-CVAD program in Burkitt's type adult acute lymphoblastic leukemia. J Clin Oncol 17 (1999), 2461–2470.
12. 12 Magrath, I, Adde, M, Shad, A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14 (1996), 925–934.
13. 13 Lee, AJ, Petroni, G, Schiffer, CA, et al. Brief-duration high-intensity chemotherapy for patients with small-non cleaved lymphoma or FAB L3 acute lymphocytic leukemia: results of Cancer and Leukemia Group B study 9251. J Clin Oncol 19 (2001), 4014–4022.
14. 14 Mead, GM, Sydes, MR, Welewski, J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma group LY06 study. Ann Oncol 13 (2002), 1264–1274.
15. 15 Todeschini, G, Bonifacio, M, Tecchio, C, et al. Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia. Am J Hematol 87 (2012), 22–25.
16. 16 Mead, GM, Barrans, SL, Qian, W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 112 (2008), 2248–2260.
17. 17 Rizzieri, DA, Johnson, JL, Byrd, JC, for the Alliance For Clinical Trials In Oncology (ACTION). Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10-002. Br J Haematol 165 (2014), 102–111.
18. 18 Hoelzer, D, Walewski, J, Dçhner, H, et al., for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood 124 (2014), 3870–3879.
19. 19 Thomas, DA, O'Brien, S, Faderl, S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106 (2006), 1569–1580.
20. 20 Corazzelli, G, Frigeri, F, Russo, F, et al. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B-cell lymphoma. Br J Haematol 156 (2012), 234–244.
21. 21 Barnes, JA, Lacasce, AS, Feng, Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol 22 (2011), 1859–1864.
22. 22 Wästerlid, T, Brown, PN, Hagberg, O, et al. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Ann Oncol 24 (2013), 1879–1886.
23. 23 Intermesoli, T, Rambaldi, A, Rossi, G, et al. High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. Haematologica 98 (2013), 1718–1725.
24. 24 Dunleavy, K, Pittaluga, S, Shovlin, M, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med 369 (2013), 1915–1925.
25. 25 Goldman, S, Smith, L, Galardy, P, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. Br J Haematol 167 (2014), 394–401.
26. 26 Coiffier, B, Lepage, E, Briere, J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346 (2002), 235–242.
27. 27 Jaffe, ES, Harris, NL, Stein, H, Vardiman, JW, (eds.) World Health Organization classification of tumours: pathology and genetics of tumours of hematopoietic and lymphoid tissues, 2001, International Agency for Research on Cancer Press, Lyon, 181–184.
28. 28 Swerdlow, SH, Campo, E, Harris, NL, et al. (eds.) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn., 2008, International Agency for Research on Cancer, Lyon.
29. 29 Murphy, SB, Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 7 (1980), 332–339.
30. 30 Cheson, BD, Horning, SJ, Coiffier, B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 4 (1999), 1244–1253.
31. 31 Machin, D, Campbell, MJ, Fayers, PM, Pinol, AP, Sample size tables for clinical studies, 2nd edn, 1997, Blackwell Science, Oxford, 251.